← Back to Search

Alkylating Agent

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1 & 2
Waitlist Available
Led By Sonali Smith
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 21 days from last treatment
Awards & highlights
Approved for 30 Other Conditions
No Placebo-Only Group

Summary

This trial is testing the side effects and best dose of lenalidomide when given with chemotherapy to treat patients with MYC-associated B-cell lymphomas. Lenalidomide works by blocking growth of new blood vessels and enzymes needed for cell growth. Chemo drugs work in different ways to stop cancer cell growth. Monoclonal antibodies may also block cancer growth.

Eligible Conditions
  • Chronic Lymphocytic Leukemia
  • Lymphoma
  • Non-Contiguous Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Hodgkin's lymphoma
  • Hodgkin's Lymphoma
  • CLL
  • Mantle Cell Lymphoma
  • Leukemia
  • MALT Lymphoma
  • Non-Hodgkin's Lymphoma
  • Chemotherapy
  • Hairy Cell Leukemia
  • Adult Diffuse Mixed Cell Lymphoma
  • Marginal Zone Lymphoma
  • Intraocular Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Splenic Marginal Zone Lymphoma
  • Cancer
  • B-Cell Non-Hodgkin Lymphoma
  • Small Intestine Lymphoma
  • Nodal Marginal Zone Lymphoma
  • Adult Diffuse Large Cell Lymphoma
  • Diffuse Mixed Cell Lymphoma
  • Testicular Lymphoma
  • Waldenström's Macroglobulinemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 21 days from last treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 21 days from last treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Add lenalidomide to the DA-EPOCH-R regimen as a front-line therapy in patients with DHL lymphomas (Phase I)
Incidence of adverse events, defined as the occurrence of all grades of toxicity (using CTCAE version 4.0)

Side effects data

From 2012 Phase 3 trial • 198 Patients • NCT00064038
78%
Fatigue (asthenia, lethargy, malaise)
78%
Hemoglobin
55%
Glucose, serum-high (hyperglycemia)
50%
Leukocytes (total WBC)
48%
Constipation
48%
Calcium, serum-low (hypocalcemia)
45%
Potassium, serum-low (hypokalemia)
40%
Platelets
40%
Lymphopenia
38%
Neutrophils/granulocytes (ANC/AGC)
33%
Edema: limb
33%
Albumin, serum-low (hypoalbuminemia)
33%
Pain - Back
30%
Pain - Joint
30%
Creatinine
28%
Nausea
28%
Rash/desquamation
28%
Anorexia
25%
Pain - Muscle
23%
Diarrhea
23%
Mood alteration - depression
23%
Neuropathy: sensory
20%
Insomnia
20%
Pain - Bone
20%
Dizziness
20%
Sodium, serum-low (hyponatremia)
18%
Aspartate aminotransferase (AST), serum glutamic oxaloacetic transaminase (SGOT)
18%
Dehydration
15%
Thrombosis/thrombus/embolism
15%
Pain - Extremity-limb
13%
Inf w/normal ANC or Gr 1-2 neutrophils - Up airway
13%
Mucositis/stomatitis (clinical exam) - Oral cavity
13%
Phosphate, serum-low (hypophosphatemia)
13%
Pain - Head/headache
13%
Taste alteration (dysgeusia)
13%
Vision-blurred vision
13%
Muscle weakness, not d/t neuropathy - body/general
13%
Cough
10%
Rash: acne/acneiform
10%
Weight gain
10%
Alkaline phosphatase
10%
Bilirubin (hyperbilirubinemia)
10%
Inf w/normal ANC or Gr 1-2 neutrophils - UTI
10%
Neuropathy: motor
10%
Alanine aminotransferase (ALT), serum glutamic pyruvic transaminase (SGPT)
10%
Muscle weakness, not d/t neuropathy - Extrem-lower
8%
Pain - Chest/thorax NOS
8%
Pain-Other (Specify)
8%
Musculoskeletal/Soft Tissue-Other (Specify)
8%
Glucose, serum-low (hypoglycemia)
8%
Inf w/normal absolute neutrophil count (ANC) or Gr 1-2 neutrophils - Bronchus
8%
Cataract
8%
Pain - Abdomen, not otherwise specified (NOS)
8%
Pain - Dental/teeth/peridontal
8%
Weight loss
8%
Fever in absence of neutropenia, ANC lt1.0x10e9/L
8%
Proteinuria
5%
Hemorrhage, pulmonary/upper respiratory - Nose
5%
Dyspnea (shortness of breath)
5%
Confusion
5%
Tremor
5%
Mood alteration - agitation
5%
Inf w/normal ANC or Gr 1-2 neutrophils - Sinus
5%
Pain - Neck
5%
Rigors/chills
5%
Infection with unknown ANC - Skin (cellulitis)
5%
Sweating (diaphoresis)
5%
Osteonecrosis (avascular necrosis)
5%
Infection with unknown ANC - Sinus
5%
Inf w/normal ANC or Gr 1-2 neutrophils - Skin
5%
Metabolic/Laboratory-Other (Specify)
5%
Memory impairment
5%
Ocular/Visual-Other (Specify)
5%
Flushing
5%
Hot flashes/flushes
5%
Central nervous system (CNS) cerebrovascular ischemia
5%
Renal failure
5%
Heartburn/dyspepsia
5%
Infection with unknown ANC - Urinary tract NOS
5%
Bruising (in absence of Gr 3-4 thrombocytopenia)
5%
Calcium, serum-high (hypercalcemia)
5%
Magnesium, serum-low (hypomagnesemia)
5%
Potassium, serum-high (hyperkalemia)
5%
Triglyceride, serum-high (hypertriglyceridemia)
5%
Arthritis (non-septic)
5%
Incontinence, urinary
5%
Pain - Bladder
5%
Dermatology/Skin-Other (Specify)
5%
Photosensitivity
5%
Ulceration
5%
Hypertension
3%
Syncope (fainting)
3%
Left ventricular diastolic dysfunction
3%
Colitis
3%
Pneumonitis/pulmonary infiltrates
3%
Gastritis (including bile reflux gastritis)
3%
Obstruction, GI - Colon
3%
Death - Disease progression, not otherwise specified (NOS)
3%
Encephalopathy
3%
Somnolence/depressed level of consciousness
3%
Speech impairment (e.g., dysphasia or aphasia)
3%
Glomerular filtration rate
3%
SVT and nodal arrhythmia - Atrial tachycardia/paroxysmal atrial tachycardia (PAT)
100%
80%
60%
40%
20%
0%
Study treatment Arm
Crossover to Rev+Dex
Lenalidomide and Dexamethasone
Dexamethasone

Awards & Highlights

Approved for 30 Other Conditions
This treatment demonstrated efficacy for 30 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (lenalidomide, DA-EPOCH-R)Experimental Treatment9 Interventions
INDUCTION PHASE: Patients receive lenalidomide PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Doxorubicin
FDA approved
Cyclophosphamide
FDA approved
Lenalidomide
FDA approved
Etoposide
FDA approved
Prednisone
FDA approved
Sulfate ion
Not yet FDA approved
Rituximab
FDA approved

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor
1,058 Previous Clinical Trials
765,550 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,938 Previous Clinical Trials
41,023,124 Total Patients Enrolled
Sonali SmithPrincipal InvestigatorUniversity of Chicago
5 Previous Clinical Trials
307 Total Patients Enrolled
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top